James Parsons
Direttore/Membro del Consiglio presso DIAMEDICA THERAPEUTICS INC.
Patrimonio netto: 239 986 $ in data 30/04/2024
Posizioni attive di James Parsons
Società | Posizione | Inizio | Fine |
---|---|---|---|
DIAMEDICA THERAPEUTICS INC. | Direttore/Membro del Consiglio | 01/10/2015 | - |
Independent Dir/Board Member | 01/10/2015 | - | |
Direttore Finanziario/CFO | 20/10/2010 | 01/10/2015 | |
Segretario Aziendale | 20/10/2010 | 01/10/2015 | |
SERNOVA CORP. | Direttore/Membro del Consiglio | 19/04/2012 | - |
Independent Dir/Board Member | 19/04/2012 | - | |
ONCOLYTICS BIOTECH INC. | Direttore/Membro del Consiglio | 16/06/2022 | - |
Storia della carriera di James Parsons
Precedenti posizioni note di James Parsons
Società | Posizione | Inizio | Fine |
---|---|---|---|
TRILLIUM THERAPEUTICS | Comptroller/Controller/Auditor | 25/08/2011 | 17/11/2021 |
Direttore Finanziario/CFO | 25/08/2011 | 17/11/2021 | |
Contatto Relazioni con gli Investitori | 25/08/2011 | - | |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Direttore Amministrativo | 01/01/2003 | 01/08/2011 |
Direttore Finanziario/CFO | 01/01/2003 | 06/06/2014 | |
Segretario Aziendale | 01/08/2011 | 06/06/2014 | |
PROMIS NEUROSCIENCES, INC. | Direttore Finanziario/CFO | 01/04/2005 | 20/10/2010 |
APTOSE BIOSCIENCES INC. | Direttore Amministrativo | 01/01/2000 | 01/01/2003 |
Direttore Finanziario/CFO | 01/01/2000 | 01/01/2003 | |
TIMMINCO LIMITED | Comptroller/Controller/Auditor | 01/01/1995 | 01/01/2000 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Direttore/Membro del Consiglio | - | - |
Formazione di James Parsons
The University of Waterloo | Graduate Degree |
Statistiche
Distribuzione geografica
Canada | 10 |
Stati Uniti | 2 |
Posizioni
Director of Finance/CFO | 5 |
Director/Board Member | 4 |
Chief Administrative Officer | 2 |
Settori
Health Technology | 8 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 6 |
---|---|
PROMIS NEUROSCIENCES, INC. | Health Technology |
APTOSE BIOSCIENCES INC. | Health Technology |
TIMMINCO LIMITED | Producer Manufacturing |
DIAMEDICA THERAPEUTICS INC. | Health Technology |
SERNOVA CORP. | Health Technology |
ONCOLYTICS BIOTECH INC. | Health Technology |
Aziende private | 3 |
---|---|
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- James Parsons
- Esperienza